NeuroGenesis cell therapy improves quality of life in progressive multiple sclerosis extension study

NeuroGenesis announced new positive results from a phase 2 extension study of its autologous stem cell therapy for people living with progressive multiple sclerosis.

The study, conducted at the Hadassah University Hospital Multiple Sclerosis Center in Jerusalem, involved patients who completed the phase 2 placebo-controlled trial. These patients were treated with repeated injections of NG01 and followed for more than a year. The findings, according to NeuroGenesis, reveal that the effect of the treatment goes beyond stabilizing the disease, inducing potential neuroprotective and neuro-regenerative effects in the central nervous system.

In the extension study, serum neurofilament light chain — a marker of neuronal injury — declined by a mean of 33% over one year. Glial fibrillary acidic protein — a key marker of neuroinflammation — was also strongly downregulated, with levels dropping from an average of 165.7 pg/mL at baseline to 127.2 pg/mL after one year. Most importantly, both biomarkers were consistent across nearly all patients, indicating beneficial effects of the treatment on both the neurodegenerative and neuroinflammatory processes.

"In progressive MS, we rarely see both biological markers and clinical function improving in tandem. The fact that patients not only showed reductions in key markers of nerve damage and inflammation but also experienced meaningful gains in walking speed, cognition, and quality of life, is significant. These results point to NG01 as a therapy with the potential to truly change the treatment landscape for progressive MS," said study author Professor Dimitrios Karussis, MD, Ph.D., Hadassah University Hospital.

NG01 is a cell therapy product of autologous stromal cells derived from the bone marrow of multiple sclerosis patients. It is provided as a cell suspension for intrathecal injection.